Table 2.
Represents the possible factors affecting the prognosis of the COVID-19 vaccine-induced Bell’s palsy (n = 40).
| Characteristics | Not Recovered n (%) | Recovered n (%) | |
|---|---|---|---|
| Gender | |||
| Male | 3 (11.5) | 23 (88.5) | |
| Female | 1 (7.1) | 13 (92.9) | |
| Age | |||
| <40 | 1 (6.7) | 14 (93.3) | |
| ≥40 | 3 (12) | 22 (88) | |
| Affected side | |||
| Unilateral | 1 (4.2) | 23 (95.8) | |
| Bilateral | 3 (18.8) | 13 (81.3) | |
| Doses | |||
| The dose that led to the symptoms | |||
| NA | 1 (25) | 3 (75) | |
| First | 3 (10) | 27 (90) | |
| Second | 0 (0.0) | 6 (100) | |
| Vaccines | |||
| Type of vaccine | |||
| NA | 0 (0.0) | 1 (100) | |
| Moderna | 0 (0.0) | 5 (100) | |
| Pfizer | 1 (8.3) | 11 (91.7) | |
| AstraZeneca | 2 (18.2) | 9 (81.8) | |
| Sinovac Biotech | 0 (0.0) | 1 (100) | |
| Johnson & Johnson | 0 (0.0) | 1 (100) | |
| Sputnik V | 1 (14.3) | 6 (85.7) | |
| Vector based vaccine | 0 (0.0) | 1 (100) | |
| COVAXIN | 0 (0.0) | 1 (100) | |
| Comorbidities | |||
| Chronic Kidney disease | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| HIV | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Diabetes | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Hypertension | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 0 (0.0) | 25 (100) | |
| Yes | 2 (50) | 2 (50) | |
| Dyslipidemia | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Asthma | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Migraine | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Hyperuricemia | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 1 (3.6) | 27 (96.4) | |
| Yes | 1 (100) | 0 (0.0) | |
| Obesity | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Heart disease | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (6.9) | 27 (93.1) | |
| Thyroid dysfunction | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Cancer | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (6.9) | 27 (93.1) | |
| Poliomyelitis | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Stroke | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (6.9) | 27 (93.1) | |
| Obstructive sleep apnea | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (6.9) | 27 (93.1) | |
| Meniere’s disease | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (6.9) | 27 (93.1) | |
| Treatments | |||
| Prednisone | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 3 (15) | 17 (85) | |
| Yes | 1 (5.6) | 17 (94.4) | |
| Methylprednisolone | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 4 (11.4) | 31 (88.6) | |
| Yes | 0 (0.0) | 3 (100) | |
| Deflazacort | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 4 (10.8) | 33 (89.2) | |
| Yes | 0 (0.0) | 1 (100) | |
| IVIG | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 2 (8.3) | 22 (91.7) | |
| Yes | 2 (14.3) | 12 (85.7) | |
| Anti-viral | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 4 (12.5) | 28 (87.5) | |
| Yes | 0 (0.0) | 6 (100) | |
| Plasma exchange | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 4 (10.8) | 33 (89.2) | |
| Yes | 0 (0.0) | 1 (100) | |